Challenges and opportunities associated with targeting estrogen receptors in treating hypertension and cardiovascular disease

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 3, 2005, Pages 245-251

  Dantas, Ana Paula V ^a   Sandberg, Kathryn ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ENDOTHELIN 1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN H2; PROTEIN KINASE B; RALOXIFENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SUPEROXIDE; TAMOXIFEN; ZINC FINGER PROTEIN;

AMBULATORY MONITORING; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA HELIX; DRUG ACTIVITY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; FIRST PASS EFFECT; GENE EXPRESSION; HEART DISEASE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIGAND BINDING; LIVER METABOLISM; MEDICAL RESEARCH; META ANALYSIS; NONHUMAN; PATHOGENESIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECEPTOR AFFINITY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; SEQUENCE HOMOLOGY; SEX DIFFERENCE; VENOUS THROMBOEMBOLISM;

EID: 27144533574     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.08.014     Document Type: Review

References (63)

1. R.C. Tostes et al. Effects of estrogen on the vascular system Braz. J. Med. Biol. Res. 36 2003 1143-1158
2. (2002) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J. Am. Med. Assoc. 288, 321-333
3. V. Krishnan et al. Mechanism of action of estrogens and selective estrogen receptor modulators Vitam. Horm. 60 2000 123-147
4. E.V. Jensen and H.I. Jacobson Basic guides to the mechanism of estrogen action Rec. Prog. Horm. Res. 18 1962 314-387
5. W.B. Kannel The Framingham Study: Historical insight on the impact of cardiovascular risk factors in men versus women J. Gend. Specif. Med. 5 2002 27-37
6. J. Staessen et al. The influence of menopause on blood pressure J. Hum. Hypertens. 3 1989 427-433
7. (1995) The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regiments on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. J. Am. Med. Assoc. 273, 199-208
8. A.P.V. Dantas et al. Influence of female sex hormones on endothelium-derived vasoconstrictor prostanoid generation in microvessels of spontaneously hypertensive rats Hypertension 34 1999 914-919
9. C. Hinojosa-Laborde et al. Ovariectomy augments hypertension in aging female Dahl salt-sensitive rats Hypertension 44 2004 405-409
10. A.P. Dantas et al. Relative contribution of estrogen withdrawal and gonadotropins increase secondary to ovariectomy on prostaglandin generation in mesenteric microvessels J. Cardiovasc. Pharmacol. 43 2004 48-55
11. S. Taddei et al. Menopause is associated with endothelial dysfunction in women Hypertension 28 1996 576-582
12. K. Hisamoto et al. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells J. Biol. Chem. 276 2001 3459-3467
13. S. Wassmann et al. Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats Circulation 103 2001 435-441
14. A.P.V. Dantas et al. In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats Hypertension 39 2002 405-411
15. A.H. Wagner et al. 17beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells FASEB J. 15 2001 2121-2130
16. J.A. Ospina et al. 17beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase Stroke 33 2002 600-605
17. E.M. Golding and T.E. Kepler Role of estrogen in modulating EDHF-mediated dilations in the female rat middle cerebral artery Am. J. Physiol. 280 2001 H2417-H2423
18. S.T. Davidge and Y. Zhang Estrogen replacement suppresses a prostaglandin H synthase-dependent vasoconstrictor in rat mesenteric arteries Circ. Res. 83 1998 388-395
19. F.L. David et al. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats Hypertension 38 2001 692-696
20. S. Hulley et al. HERS Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women J. Am. Med. Assoc. 280 1998 605-613
21. D.M. Herrington et al. The estrogen replacement and atherosclerosis (ERA) study: Study design and baseline characteristics of the cohort Control Clin. Trials. 21 2000 257-285
22. F.L. Wynne et al. Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats Hypertension 43 2004 405-412
23. M.S. Post et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: A randomized, placebo-controlled study in postmenopausal women Arterioscler Thromb. Vasc. Biol. 23 2003 1116-1121
24. M.R. Owens and C.D. Cimino Diethylstilbestrol selectively modulates plasma coagulation protein synthesis by the perfused rat liver Blood 66 1985 402-406
25. M. Beato et al. Steroid hormone receptors: Many actors in search of a plot Cell 83 1995 851-857
26. K. Paech et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites Science 277 1997 1508-1510
27. T. Barkhem et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists Mol. Pharmacol. 54 1998 105
28. F. Delaunay et al. Functional differences between the amino-terminal domains of estrogen receptors α and β Mol. Pharmacol. 58 2000 584-590
29. J.F. Couse et al. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα- knockout mouse Endocrinology 138 1997 4613-4621
30. W. Tschugguel et al. Distinct expression pattern of estrogen receptor-α and -ß mRNA in cultured human endothelial and vascular smooth muscle cells J. Soc. Gynecol. Invest. 5 1998 143A
31. B. Darblade et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor Circ. Res. 90 2002 413-419
32. P. Zhai et al. Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice Am. J. Physiol. Heart Circ. Physiol. 278 2000 H1640-H1647
33. M.D. Iafrati et al. Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice Nat. Med. 3 1997 545-548
34. R.H. Karas et al. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice PNAS 96 1999 15133-15136
35. R.H. Karas et al. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice Circ. Res. 89 2001 534-539
36. Y. Zhu et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta Science 295 2002 505-508
37. J. Widder et al. Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR Hypertension 42 2003 991-996
38. K.S. Russell et al. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling PNAS 97 2000 5930-5935
39. H.P. Kim et al. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae Biochem. Biophys. Res. Commun. 263 1999 257-262
40. D.W. Losordo et al. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women Circulation 89 1994 1501-1510
41. W.S. Post et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system Cardiovasc. Res. 43 1999 985-991
42. N.J. McKenna et al. Nuclear receptor coregulators: Cellular and molecular biology Endocr. Rev. 20 1999 321-344
43. Georgescu, S.P. et al. (2005) Modulator recognition factor 1 (MRF1), an ARID-family member, is a novel co-repressor for estrogen receptor {alpha}. Mol. Endocrinol., doi:10.1210/me.2004-0311
44. H.W. Ward Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels Br. Med. J. 1 1973 13-14
45. W.G. Ryan et al. Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study Osteoporos. Int. 2 1991 39-41
46. C.A. Hulka and D.A. Hall Endometrial abnormalities associated with tamoxifen therapy for breast cancer: Sonographic and pathologic correlation AJR Am. J. Roentgenol. 160 1993 809-812
47. A.D. Palkowitz et al. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: A novel, highly potent, selective estrogen receptor modulator J. Med. Chem. 40 1997 1407-1416
48. M. Maricic and O. Gluck Review of raloxifene and its clinical applications in osteoporosis Expert Opin. Pharmacother. 3 2002 767-775
49. C.P. Miller SERMs: Evolutionary chemistry, revolutionary biology Curr. Pharm. Des. 8 2002 2089-2111
50. O.B. Wallace et al. Estrogen receptor modulators: Relationships of ligand structure, receptor affinity and functional activity Curr. Top Med. Chem. 3 2003 1663-1682
51. G.A. Figtree et al. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism J. Pharmacol. Exp. Ther. 295 2000 519-523
52. P. de Medina et al. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells J. Pharmacol. Exp. Ther. 308 2004 1165-1173
53. K.S. Stamatelopoulos et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women Am. Heart J. 147 2004 1093-1099
54. T. Hayashi et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system Biochem. Biophys. Res. Commun. 214 1995 847-855
55. G.B. Stefano et al. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia Circulation 101 2000 1594-1597
56. S. Wassmann et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production Circulation 105 2002 2083-2091
57. T. Simoncini et al. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene Circulation 105 2002 1368-1373
58. K.N. Abdullah et al. Effectiveness and safety of raloxifene in post-menopausal females J. Coll. Phys. Surg. Pak. 15 2005 266-269
59. E. Sbarouni et al. The effects of raloxifene and simvastatin on plasma lipids and endothelium Cardiovasc. Drugs Ther. 17 2003 319-323
60. D. Agnusdei and N. Iori Raloxifene: Results from the MORE study J. Musculoskelet. Neuronal Interact. 1 2000 127-132
61. R.S. Blumenthal et al. Cardiovascular effects of raloxifene: The arterial and venous systems Am. Heart J. 147 2004 783-789
62. L. Mosca et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study Am. J. Cardiol. 88 2001 392-395
63. L. Mosca Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial Ann. N. Y. Acad. Sci. 949 2001 181-185